HR 6576
115th Congress
House
Health
Drug safety, medical device, and laboratory regulation
Licensing and registrations
Marketing and advertising
Drug-Price Transparency in Communications Act
Introduced: July 26, 2018
Introduced by:
Schakowsky, Janice D.
Democratic
· Illinois
See on congress.gov
Everywhere this bill has been
3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jul 27, 2018
Referred to the Subcommittee on Health.
Jul 26, 2018
Referred to the House Committee on Energy and Commerce.
Jul 26, 2018
Introduced in House
Plain-English summary
Drug-Price Transparency in Communications Act
This bill amends the Federal Food, Drug, and Cosmetic Act to impose a civil penalty on any person who disseminates a direct-to-consumer drug advertisement that does not include the wholesale acquisition cost (the manufacturer's list price to wholesalers or direct purchasers) for a 30-day supply of the drug.
The bill requires any representative of a drug manufacturer who communicates with a health care practitioner about a drug manufactured by the drug manufacturer to disclose the wholesale acquisition cost for a 30-day supply of the drug.
What's happening now
Referred to the Subcommittee on Health.
Committees of jurisdiction
2